Summary

Global Colorectal Cancer Screening and Diagnostic Market was valued at USD 15.08 Billion in 2024 and is expected to reach USD 20.63 Billion in the forecast period with a CAGR of 5.34% through 2030. The Global Colorectal Cancer Screening and Diagnostic Market is witnessing significant growth due to increasing global awareness regarding cancer prevention, early detection, and advancements in diagnostic technologies. Rising incidence rates of colorectal cancer, particularly among individuals aged 50 and above, are propelling the demand for early and accurate screening methods. Governments and healthcare organizations are launching awareness campaigns that emphasize the importance of routine screening, contributing to a surge in testing volumes. Public-private partnerships and healthcare funding initiatives are enabling greater access to diagnostic services, especially in underserved populations. Moreover, the growing acceptance of non-invasive screening methods such as fecal immunochemical tests (FIT), fecal DNA tests, and blood-based diagnostics is making screening more accessible and acceptable to a broader patient demographic.
Technological innovations are playing a vital role in reshaping the market landscape. The development of AI-based colonoscopy systems, digital pathology tools, and liquid biopsy technologies is improving detection accuracy and reducing the need for invasive procedures. Integration of machine learning in diagnostic imaging is assisting clinicians in identifying polyps and early-stage tumors more effectively. Rising interest in home-based and point-of-care testing options is also transforming patient behavior, with more individuals opting for convenient, self-administered diagnostic tools. Leading diagnostic companies are investing in research to enhance biomarker-based screening approaches that offer higher specificity and sensitivity, which is opening new revenue streams. The emergence of multi-cancer detection panels, which include colorectal cancer markers, is expected to further stimulate innovation and competition within the industry.
Key Market Drivers
Advancements in Technology
High-definition (HD) colonoscopy utilizes advanced imaging technology to provide clearer and more detailed images of the colon, enhancing the detection of precancerous polyps and early-stage colorectal cancer during procedures. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were 142,462 reported cases of colon and rectum cancer in the United States, emphasizing the importance of improved detection methods.
Key Market Challenges
False Positives and Over diagnosis
False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present. False positives can cause unnecessary anxiety and stress for patients. They often lead to additional testing and procedures, which can be invasive and carry their own risks. False positives can result in increased healthcare costs due to follow-up tests and procedures. This can strain healthcare resources and increase the financial burden on individuals and healthcare systems. Experiencing a false positive result can deter individuals from participating in future screening, as they may be apprehensive about undergoing another potentially stressful experience. Over diagnosis occurs when a screening test detects a condition that, if left untreated, would not have progressed to clinical significance, or caused harm during the patient's lifetime. Over diagnosis can lead to unnecessary treatment, including surgery, chemotherapy, or radiation therapy. These interventions can have physical and psychological side effects. Treating cases that would not have caused harm can lead to overtreatment, which poses risks to the patient's overall health and quality of life.
Key Market Trends
Shift Towards Non-Invasive Tests
Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates. The avoidance of invasive procedures can reduce patient discomfort and anxiety associated with colorectal cancer screening. This can encourage individuals to undergo testing. Non-invasive tests often require minimal preparation and can be performed at home, making them more convenient for patients. This convenience can lead to higher compliance with screening recommendations. Unlike colonoscopy, which typically requires sedation or anesthesia, non-invasive tests do not involve the use of these medications, eliminating the associated risks and recovery time. Non-invasive tests are generally more cost-effective compared to invasive procedures like colonoscopy, making them an attractive option for both patients and healthcare systems. Some non-invasive tests, such as stool-based tests, can be performed more frequently, allowing for regular monitoring and early detection of changes in colorectal health. Non-invasive tests can be used to reach populations with limited access to healthcare facilities or those who may be hesitant to undergo invasive procedures. Advances in non-invasive screening technologies, such as the development of highly sensitive fecal immunochemical tests (FIT), have improved their ability to detect colorectal cancer and precancerous lesions.
Key Market Players
• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc.
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Novigenix SA
• FUJIFILM Holdings Corporation
• Olympus Corporation
• QuidelOrtho Corporation
Report Scope:
In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Colorectal Cancer Screening and Diagnostic Market, By Screening:
o Stool-Based Test
o Colonoscopy and Sigmoidoscopy
o Others
• Colorectal Cancer Screening and Diagnostic Market, By Diagnostics:
o Biomarker Test
o Colonoscopy
• Colorectal Cancer Screening and Diagnostic Market, By End User:
o Hospitals and Clinics
o Clinical Laboratories
o Others
• Colorectal Cancer Screening and Diagnostic Market, By region:
o North America
§ United States
§ Canada
§ Mexico
o Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o Europe
§ Germany
§ France
§ United Kingdom
§ Spain
§ Italy
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.
Available Customizations:
Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Colorectal Cancer Screening and Diagnostic Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others)
5.2.2. By Diagnostic (Biomarker Test, Colonoscopy)
5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Screening
6.2.2. By Diagnostics
6.2.3. By End User
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Screening
6.3.1.2.2. By Diagnostics
6.3.1.2.3. By End User
6.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Screening
6.3.2.2.2. By Diagnostics
6.3.2.2.3. By End User
6.3.3. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Screening
6.3.3.2.2. By Diagnostics
6.3.3.2.3. By End User
6.3.4. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Screening
6.3.4.2.2. By Diagnostics
6.3.4.2.3. By End User
6.3.5. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Screening
6.3.5.2.2. By Diagnostics
6.3.5.2.3. By End User
7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Screening
7.2.2. By Diagnostics
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Colorectal Cancer Screening and Diagnostic Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Screening
7.3.1.2.2. By Diagnostics
7.3.1.2.3. By End User
7.3.2. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Screening
7.3.2.2.2. By Diagnostics
7.3.2.2.3. By End User
7.3.3. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Screening
7.3.3.2.2. By Diagnostics
7.3.3.2.3. By End User
7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Screening
7.3.4.2.2. By Diagnostics
7.3.4.2.3. By End User
7.3.5. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Screening
7.3.5.2.2. By Diagnostics
7.3.5.2.3. By End User
8. North America Colorectal Cancer Screening and Diagnostic Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Screening
8.2.2. By Diagnostics
8.2.3. By End User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Screening
8.3.1.2.2. By Diagnostics
8.3.1.2.3. By End User
8.3.2. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Screening
8.3.2.2.2. By Diagnostics
8.3.2.2.3. By End User
8.3.3. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Screening
8.3.3.2.2. By Diagnostics
8.3.3.2.3. By End User
9. South America Colorectal Cancer Screening and Diagnostic Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Screening
9.2.2. By Diagnostics
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Screening
9.3.1.2.2. By Diagnostics
9.3.1.2.3. By End User
9.3.2. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Screening
9.3.2.2.2. By Diagnostics
9.3.2.2.3. By End User
9.3.3. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Screening
9.3.3.2.2. By Diagnostics
9.3.3.2.3. By End User
10. Middle East and Africa Colorectal Cancer Screening and Diagnostic Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Screening
10.2.2. By Diagnostics
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Screening
10.3.1.2.2. By Diagnostics
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Screening
10.3.2.2.2. By Diagnostics
10.3.2.2.3. By End User
10.3.3. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Screening
10.3.3.2.2. By Diagnostics
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Colorectal Cancer Screening and Diagnostic Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Clinical Genomics Technologies Pty Ltd.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Danaher Corporation
16.3. DiaCarta, Inc
16.4. Eiken Chemical Co., Ltd.
16.5. Epigenomics AG
16.6. Freenome Holdings, Inc.
16.7. Guardant Health, Inc
16.8. FUJIFILM Holdings Corporation
16.9. Novigenix SA
16.10. QuidelOrtho Corporation
16.11. Olympus Corporation
16.12. Lepu Medical Technology (Beijing) Co., Ltd.
17. Strategic Recommendations
18. About Us & Disclaimer